254 Results
Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone , M.D., Ph.D.
Biodesix announced today that the United States Patent and Trademark Office has awarded to the company patent number 7,736,905.
Biodesix's Paul Beresford will present at the 2011 Biotech Showcase conference taking place January 10–12th at the Parc 55 Wyndham in San Francisco, CA
Biodesix's CEO, David Brunel, will present at the 2010 Personalized Medicine Partnerships conference, Wednesday, February 24th, at 11:00 a.m. eastern time.
Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.
Biodesix Inc. announced today that they are one of the winners of the 2010 Colorado Companies to Watch award, developing valuable products and services.
Biodesix announced today that it has completed $10 million in Series B-1 financing round. The financing was led by existing shareholders and board members.
Biodesix has received the clinical laboratory evaluation program certification from the New York State Department of Health’s Wadsworth Center.
Biodesix announced that the U.S. Patent & Trademark Office has issued four patents for the protection of the company's products and technology.
Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors.